Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 3, 2005. The report details specific corporate actions regarding directors' interests in ordinary shares and a share repurchase transaction executed on March 2, 2005.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on share capital movements.
- Share Repurchase Price: 1,277.86 pence per share.
- Treasury Shares Held: 76,648,000 shares (post-transaction).
- Shares in Issue: 5,863,147,366 shares (excluding Treasury shares).
Material Changes
Two material changes regarding share ownership were reported:
- Employee Trust Transfer: On March 1, 2005, the GlaxoSmithKline Employee Trust transferred 51,710 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. Directors Dr. J-P Garnier, Dr. T Yamada, and Mr. J D Coombe hold interests in the trust as potential beneficiaries.
- Share Buyback: On March 2, 2005, the Company purchased 400,000 Ordinary shares under authority granted at the May 17, 2004 Annual General Meeting. These shares were placed in Treasury.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a procedural disclosure of share transactions.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (76,648,000) against the company's latest capitalization table.
- Confirm the impact of the 400,000 share repurchase on the weighted average shares outstanding for earnings calculations.
- Review the terms of the SmithKline Beecham Employee Share Option Plan 1991 to understand the vesting conditions for the 51,710 shares transferred.
- Check subsequent filings for further share buyback activity under the authority granted in May 2004.